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Abstract
Lysine-specific methyltransferase 2A (KMT2A) is responsible for methylation of histone H3 (K4H3me) and contributes to
chromatin remodeling, acting as “writer” of the epigenetic machinery. Mutations in KMT2A were first reported in
Wiedemann–Steiner syndrome (WDSTS). More recently, KMT2A variants have been described in probands with a specific
clinical diagnosis comprised in the so-called chromatinopathies. Such conditions, including WDSTS, are a group of
overlapping disorders caused by mutations in genes coding for the epigenetic machinery. Among them, Rubinstein–Taybi
syndrome (RSTS) is mainly caused by heterozygous pathogenic variants in CREBBP or EP300. In this work, we used next
generation sequencing (either by custom-made panel or by whole exome) to identify alternative causative genes in
individuals with a RSTS-like phenotype negative to CREBBP and EP300 mutational screening. In six patients we identified
different novel unreported variants in KMT2A gene. The identified variants are de novo in at least four out of six tested
individuals and all of them display some typical RSTS phenotypic features but also WDSTS specific signs. This study
reinforces the concept that germline variants affecting the epigenetic machinery lead to a shared molecular effect (alteration
of the chromatin state) determining superimposable clinical conditions.
Introduction
Lysine-specific methyltransferase 2A (KMT2A, OMIM
+159555) located at 11q23.3 contributes to chromatin
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opening, acting as “writer” of the epigenetic machinery.
This gene encodes for a DNA-binding protein that methy-
lates lysine 4 of histone H3 (K4H3me), which positively
regulates transcription of multiple genes, including those
involved in hematopoiesis and neuronal development [1].
KMT2A is expressed ubiquitously in human tissues and has
been broadly studied in hematological diseases, since
somatic translocations at its locus characterize a subset of
acute leukemias [2]. More recently, heterozygous KMT2A
loss-of-function and missense variants have been associated
to Wiedemann–Steiner syndrome (WDSTS, OMIM
#605130), described for the first time in 1989 by Wiede-
mann et al. [3] and characterized by hypertrichosis cubiti,
intellectual disability (ID) and developmental delay, a dis-
tinctive facial appearance and short stature [4].
Since 2012, pathogenic variants have been reported in
patients with a typical WDSTS phenotype [4–11] and most
of them generate a truncated protein. Additional variants
have been annotated by exome sequencing performed for
undiagnosed genetic disorders (https://decipher.sanger.ac.
uk/). Studies in large cohorts of syndromic/non-syndromic
ID and neurodevelopmental disorders with heterogeneous
phenotype have led to the identification of further 32
KMT2A novel variants [12–15]. In addition, Li et al. have
described 11 unreported mutations in a study comparing
French and Chinese cohorts [15, 16]. Besides WDSTS,
deleterious variants in KMT2A were also described in
association with epilepsy [17], primary immunodeficiency
[18], and eosinophilia [19].
Interestingly, five more patients carrying KMT2A var-
iants were clinically diagnosed with Coffin–Siris syndrome
(CSS, OMIM #135900, #614608, #614607, #614609,
#616938, #615866, #617808, #618362, #618027, #618506)
(pt #K2431) [20], Cornelia de Lange syndrome (CdLS,
OMIM #122470, #300590, #610759, #614701, #300882)
(pt CdLs #3 and pt #1) [21, 22], Kabuki syndrome (KS,
OMIM #147920, #300867) (pts #KS8-KS29) [23], and
Rubinstein–Taybi syndrome (RSTS, OMIM #180849,
#613684) (pt #103) [24] respectively (Supplementary
Table S1). To note, all the above-mentioned syndromes and
WDSTS are typical epigenetic machinery disorders, also
called chromatinopathies, a group of diseases caused by
alterations in genes coding for components of the epigenetic
apparatus termed “writers, erasers, readers, and remodelers”
[25]. These proteins act in concert to control the chromatin
opening and closing thus regulating gene expression by
modification (i.e., methylation, acetylation, etc.) of histones
and DNA.
As well as KMT2A, protein products of RSTS causative
genes, CBP and p300, are “writers” of the epigenetic
machinery. Both are ubiquitously expressed homologous
proteins belonging to the KAT3 family of lysine acetyl-
transferases [26]. CBP and p300 are encoded by CREB
binding protein (CREBBP, also known as “CBP”) and E1A-
associated protein p300 (EP300) respectively. Mutations in
the “major gene” CREBBP, located at 16p13.3, are
responsible for ~60% of RSTS patients [27], while almost
10% of RSTS cases have been diagnosed for pathogenic
variants in EP300, mapping on chromosome 22q13.2 and
called the “minor gene” [28]. RSTS is a rare (1:125,000)
autosomal-dominant disorder which, generally, occurs de
novo [29] and displays phenotypically heterogeneous
variability. RSTS peculiar clinical picture includes postnatal
growth deficiency, microcephaly, specific dysmorphisms,
and skeletal abnormalities (e.g., broad thumbs and big toes).
All these signs are hallmarks frequently used for clinical
diagnosis, with a wide spectrum of multiple congenital
anomalies [30].
To investigate the molecular basis of patients with a
suspicious of RSTS diagnosis but without causative variants
in CREBBP and EP300, we performed a whole exome/
targeted next generation sequencing (NGS) identifying six
different novel variants in KMT2A. The identified variants
are de novo in at least four out of six tested patients (parents
are unavailable in two families) and unreported. The clinical
reevaluation of patients shows that they display some
typical RSTS features but also various WDSTS specific
signs with a peculiar global clinical presentation suggesting
that different alterations of epigenetic machinery genes can
converge to the same molecular effect (alteration opening/
closing chromatin) to determine overlapping clinical
conditions.
Materials and methods
Subjects
Individuals with RSTS initial diagnosis were clinically
assessed and diagnosed by the respective clinical geneticist
to enter genetic analysis and then carefully phenotypically
reevaluated by a single geneticist with a deep expertise in
RSTS diagnosis (DM). Informed consent was obtained from
all enrolled subjects and families and this study was
approved by the local institution ethical committee and
review board.
CREBBP and EP300 molecular analysis
A molecular multi-method approach based on a combina-
tion of multiple ligation-dependent probe amplification
(MLPA) to detect whole gene or intragenic deletions and
direct Sanger sequencing to identify point variants was
applied. Genomic DNA was extracted from peripheral
blood samples in EDTA using DNeasy Blood and Tissue
Kit (Sigma-Aldrich, St. Louis, MO, USA) for MLPA
E. Di Fede et al.
analysis, or with Wizard® Genomic DNA Purification Kit
(Promega, Madison, WI, USA) for sequencing. MLPA
analysis was performed with the SALSA MLPA commer-
cially available kits (P313-A for CREBBP and P333-A1 for
EP300) (MRC-Holland, Amsterdam, NL) according to the
manufacturer’s protocol. Amplified products were separated
by capillary electrophoresis using an ABI PRISM 3700
Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA) and data were visually inspected using GeneMaker
software v.1.5 (SoftGenetics, LLC, State College, PA,
USA) and then deeply analyzed using Coffalyser (MRC-
Holland). CREBBP amplicons encompassing coding
regions and splicing junctions were amplified from the
genomic DNA of patients #208 and #221 using GoTaq
Flexi DNA Polymerase (Promega) and primer’s couples
were designed with the public software Primer3 (http://
bioinfo.ut.ee/primer3-0.4.0/) and OligoAnalyser 3.1 (https://
eu.idtdna.com/calc/analyzer). Amplified fragments were
sequenced with the same primers using the Big Dye Ter-
minator v.1.1 or v.3.1 Cycle Sequencing Kit (Applied
Biosystems) and the ABI PRISM 3130 sequencer (Applied
Biosystems) according to the manufacture’s protocol.
Electropherograms were analyzed with ChromasPro soft-
ware 1.7.5 (Technelysium Pty Ltd., Queensland, AUS)
considering the NG_009873.2 sequence as reference for
CREBBP.
Multigene panel sequencing and data analysis
All the patients here described, except patient #187, have
been tested by multigene panel sequencing. A customized
HaloPlex Target Enrichment NGS panel (Agilent Tech-
nologies, Santa Clara, CA, USA) was generated using
Agilent’s SureDesign tool available at www.agilent.com/
genomics/suredesign. A library of all the coding exons and
intron–exon boundaries of 68 known genes associated with
more than 40 OMIM entries, selected as classified as known
chromatinopathies [25], was prepared using the HaloPlex
HS Target Enrichment System (Agilent Technologies).
Total genome target spanned 384 kb and was theoretically
estimated to be completely covered (99.82%). A total of
17,470 amplicons were generated. Libraries were prepared
according to the manufacturer’s protocol using the human
reference genome GRCh37/hg19. The library was then
amplified by PCR to produce a sequencing-ready, target-
enriched sample. Fragmented gDNA and final libraries were
evaluated using High Sensitivity D1000 ScreenTape Sys-
tem on TapeStation 2200 (Agilent Technologies) and Qubit
dsDNA Hs Assay Kits on Qubit® 4 Fluorometer (Thermo
Fisher Scientific, Waltham, MA, USA) to quantify,
according to the manufacturer’s instructions. Sequencing
was performed on Illumina MiSeq System, using the MiSeq
Reagent Kit V2-500 cycles (Illumina, San Diego, CA,
USA), yielding 151 bp-long paired-end reads and achieving
an average read depth of at least 400× for 11–22 samples
and at least 20× per-base coverage in more than 98% of the
targeted regions. Quality of sequences was preliminary
checked with FastQC and trimmed using Trimmomatic
(PMID: 24695404) if the quality of at least half-read was
lower than 10 (phred quality score). Residual adapter
sequences were removed by cutadapt (https://cutadapt.rea
dthedocs.io/en/stable/). Preprocessed reads were aligned
against the GRCh37/hg19 reference genome sequence by
BWA-0.7.17 software. Depth of coverage statistics for the
target regions were calculated by means of TEQC (https://
doi.org/10.18129/B9.bioc.TEQC) and other custom scripts.
Variants were identified by means of the Haplotype Caller
tool of GATK v. 3.8 and were annotated with ANNOVAR,
using RefSeq gene and transcript annotations (updated to
Dec 2016). Variants were sought in the most important
public collections, including dbSNP v. 150, ExAC v. 0.3,
Exome Variant Server, gnomAD, HRC, Kaviar and Clin-
Var. Sequencing artefacts were controlled by matching
individual-specific variants against an internal database of
variants. Missense variants were fully annotated using
dbNSFP v3.5 from which we have retrieved precomputed
pathogenicity predictions and evolutionary conservation
predictions and measures. The significance of candidate
variants was classified according to American College of
Medical Genetics and Genomics (ACMG) criteria using
InterVar (http://wintervar.wglab.org/) (https://doi.org/10.
1016/j.ajhg.2017.01.004) and Varsome (https://varsome.
com/) (https://doi.org/10.1093/bioinformatics/bty897) tools.
Exome sequencing
Patient #187 and his parents has been tested by exome
sequencing. Genomic DNA was extracted from whole
blood for DNA library preparation and exome enrichment
using the Agilent SureSelect V7 kit according to manu-
facturer instructions. Quality of post-amplification libraries
was assessed using DNA 1000 chips on the BioAnalyzer
2100 (Agilent) and Qubit fluorimetric quantitation using
Qubit dsDNA BR Assay Kits (Invitrogen by Thermo Fisher
Scientific). An indexed 150 bp paired-end sequencing run
was performed on an Illumina HiSeq 3000 instrument at
CRS4 NGS facility. This approach achieved a 75× average
coverage over the 36Mb of genomic regions sequenced,
with 97% regions covered at least 10×. Data analysis has
been performed using an analysis pipeline based on public
tools. In brief, paired-end sequence reads were aligned to
the human genome (hg19) with the Burrows–Wheeler
Aligner (BWA MEM) using default settings. Initial map-
pings were processed using the GATK framework
(v4.1.0.0) according to their Best Practices recommenda-
tions. Variant sites were identified using GATK Haplotype
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Caller module. Variants were classified as known or novel
based on dbSNP146 and annotated using KGGSeq. Anno-
tations were retrieved from dbNSFP v.3.0 and included
positions in UCSC, RefGene, GENCODE, and ENSEMBL
transcripts, OMIM and ClinVar annotations, allele fre-
quency in dbSNP, ESP6500 (release SI-V2), 1000 Genomes
Project (release 05/2013), ExAC and gnomAD, functional
predictions for the amino-acid changes according to dif-
ferent models (SIFT, PolyPhen2, LRT, Pathogenic var-
iantTaster, Pathogenic variantAssessor, and FATHMM).
We filtered the identified variants according to recessive/
dominant/de novo pattern of inheritance, gene features and
MAF < 1% using as references dbSNP138, dbSNP141,
1000 Genomes, ESP6500, ExAC, and gnomAD. Subse-
quently, variants were evaluated for their phenotypic and
biological impact.
Variants validation and segregation analysis
Variants of interest were confirmed by Sanger sequencing
following PCR amplification and segregation analysis was
performed in the available family trio. PCR reactions were
ruled following the protocol for GoTaq Flexi DNA Poly-
merase (Promega) with patients’ and variants’ specific pri-
mer sets considering NG_027813.1 as reference for KMT2A
gene. The same pairs of primers were used for Sanger
sequencing. KMT2A exons are numbered like in
ENST00000534358.8 reference. Sequence variants were
described according to HGVS nomenclature guidelines
(https://varnomen.hgvs.org/) and reported in LOVD (https://
databases.lovd.nl/shared/genes/KMT2A) as individual IDs
#00275545 (pt #208), #00275547 (pt #250), #00275548 (pt
#187), #00275549 (pt #251), #00275550 (pt #243), and
#00275551 (pt #221).
Results
KMT2A detected variants
CREBBP and EP300 MLPA analysis was previously per-
formed for all the six described patients and resulted
negative. Patients #187, #208, and #221 underwent also
CREBBP direct sequencing, without detecting pathogenic
variants. Hence, we performed NGS analysis with a custom-
made panel comprising 68 genes known as causative of
chromatinopathies [25], including CREBBP and EP300
genes, to 30 patients, including all the patients here
described, except patient #187. NGS exome analysis was
applied to #187 trio and additional nine patients. We
detected in six patients (five out of 30 tested by multigene
panel sequencing and one out of 10 analysed by WES) a
novel heterozygous variant in KMT2A (Table 1).
In particular, patient #208 was found carrier of a de novo
nucleotide substitution in exon 3: c.553C>T, predicted to
cause a premature stop codon p.(Arg185*); patient
#250 shows a 21 nucleotides insertion in exon 3:
c.1697_1717dup, resulting in an aminoacidic in frame
duplication p.(Leu566_Leu572dup). Patient #250 parents’
DNA is not available for further testing.
Patients #187, #251, and #243 are carriers of three dif-
ferent de novo variants in exon 6: a single nucleotide change
c.3596G>A leading to a premature stop codon p.
(Trp1199*) in patient #187, a single nucleotide deletion
c.3603del, causing a frameshift p.(Ser1202Profs*12) in
patient #251 and a five nucleotides deletion c.3632_3634
+2del involving the last three nucleotide of exon 6 and the
first two bases of the following intronic sequence, sug-
gesting a possible effect on the correct splicing, in patient
#243.
Finally, patient #221 is carrier of a four nucleotides
duplication in exon 7 c.3897_3900dup, leading to a fra-
meshift p.(Leu1303Serfs24*). The patient is adopted,
making impossible verifying the de novo origin of this
variant.
According to ACMG guidelines, the clinical significance
of the variants is pathogenic for patients #208, #187, #251,
and #243 as all the variants meet the same ACMG criteria
(PVS1, PM2, and PP3). Variant detected in patient #250 has
been classified with uncertain significance (PM2, PM4, and
BP4), probably due to the lack of predicted impact on gene
product, while patient #221 was found carrier of a likely
pathogenic variant (PVS1, PM2).
Clinical phenotypes
Patient #208
The patient is a 13 years old boy, born with normal birth
parameters. Postnatal growth deficiency was reported.
Minor facial anomalies were evident such as downslanting
palpebral fissures, columella below the alae nasi, grimacing
smile and hypertelorism, broad nasal bridge, long eyelashes,
and prominent eyes. Angulated thumbs and broad halluces
are present. He shows severe ID and behavioral issues, with
aggression. In addition, C2–C3 vertebral fusion, organo-
megaly, and cerebellar vermis hypoplasia were reported.
Patient #250
Patient 250 is a 16 years old boy. A RSTS diagnosis was
suspected for the presence of dysmorphisms such as colu-
mella below the alae nasi, grimacing smile, and for the
skeletal anomalies of hand and feet (broad thumbs and
halluces). Unfortunately, parents of patient 250 refuse a
clinical reevaluation of their son and are unavailable to give
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their DNA making impossible test the de novo origin of
KMT2A variant, detected in the son.
Patient #187
Patient 187 is a 17 years old boy, born after an uneventful
pregnancy with normal birth parameters (weight 3.045 kg,
length 47 cm; occipitofrontal circumference (OFC) 33.5 cm,
APGAR 8/9). Neonatal hypotonia, a sacral dimple (S4–S5)
and postnatal growth deficiency were described. He fur-
thermore had a diagnosis of precocious puberty. Psycho-
motor development was delayed, with a moderate ID and
some behavioral difficulty (anxiety in particular). Cerebral
and medullary MRI showed craniocervical junction
anomalies with a mild basilar impression. Clinical evalua-
tion pointed out a relative macrocephaly, low anterior
hairline, synophrys, long eyelashes, bulbous nose, low set
ears, upturned corners of mouth, broad thumbs and hal-
luces, and hirsutism.
Patient #251
Patient #251 is a 25 years old girl, born after an uneventful
pregnancy with normal birth parameters (weight 3.100 kg).
A gastroesophageal reflux was described. Psychomotor
development was delayed, with a moderate ID. Cerebral
and medullary MRI showed craniocervical junction
anomalies with a mild basilar impression. Clinical evalua-
tion pointed out long eyelashes, long and downslanting
palpebral fissures, strabismus, epicanthal folds, hypertelor-
ism, high nasal bridge, columella below alae nasi, upturned
corners of mouth, broad halluces, and kyphoscoliosis.
Patient #243
Patient #243 is a 26 years old boy, born at 35 weeks of
gestation. Parents were healthy and non-consanguineous.
The pregnancy showed several threatened miscarriages.
Weight was 2.750 kg (+0.66 SD), APGAR score 7 and 8 at
1 and 5 min respectively. At the birth: transient polypnea of
the newborn and cyanosis, jaundice treated with photo-
therapy are recorded. Around the age of 6 months, he
showed growth and psychomotor retardation and hypotonia.
At the auxological evaluation at 10 months of age: length
was 67 cm (<3rd centile), weight 6.8 kg, OFC 44.3 cm. GH
deficit was diagnosed at 2 years of life and GH therapy was
started with good results and continued until 14.5 years.
Early puberty was diagnosed at 7 years of life and treated
with triptorelin therapy until 9.5 years. Final height was
164.8 cm (3rd centile), target height 171.5 cm (25th centile).
At the clinical evaluation hypotonia, hypertricosis, facial
dysmorphisms (telecanthus, downslanted and narrow pal-
pebral fissures, and long eyelashes), broad thumbs, and
broad distal fingertips were reported. Strabismus has been
surgically corrected at 2.5 years of age. Speech language
was delayed and he showed learning disability, mild ID and
aggressive behavior. At the last examination at 21 years of
age aggressive behavior with selective feeding has been
confirmed.
Patient #221
Patient #221 is a 9 years old male child. He was adopted
and the only information on biological family is that the
parents were non-consanguineous. He showed dysmorph-
isms such as coarse face, low anterior airline, synophrys,
narrow forehead, hypertelorism, high arched and heavy
eyebrows, long eyelashes, narrow and downslanting pal-
pebral fissures, convex nasal bridge, short philtrum, thin
lips, high-arched and narrow-palate, micrognathia and
abnormal ears, and skeletal anomalies such as brachy-
dactyly, broad and angulated thumbs, broad halluces and
kyphosis. Clinical examination also reveals hirsutism,
hypertrichosis, mobile testis and anamnestic record disclose
Fig. 1 Features of patients #187, #243, and #251, found carriers of
KMT2A variants. Facies appearance of patient #187 was shown at
neonatal age, at 2 and 10 years with particular of hand and foot (a).
Facies of patient #243 at 2, at 9 and 23 years and hands/feet particulars
(b). Facies and foot (c) particular of patient #251 at 16 years.
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feeding problems, postnatal growth retardation, psycho-
motor delay (hypotonia, delayed erected head, sat and
walked independently, and began speaking words at 4
years), and severe ID. At the age of 7.5 years his weight was
22.750 kg (10–25th pc), his height was 106 cm (<−3 SD),
and his OFC measured 46.2 cm (<−4 SD). Electro-
encephalogram and cerebral MRI did not reveal any brain
abnormalities; visual evoked potential and auditory brain
stem responses to complex sounds (cABRs) were normal
too. Ultrasound of the abdomen, ECG, and echocardio-
graphy were normal.
Table 1 summarizes the clinical features of six patients
here described, comparing the clinical signs of each patient
and the typical features of RSTS and WDSTS.
There are many clinical signs shared by RSTS and
WDSTS patients described in the literature (growth retar-
dation, ID, and specific dysmorphisms). The clinical ree-
valuation of patients shows that they display some typical
RSTS features that appear more evident during childhood,
but also various WDSTS specific signs with a peculiar
global clinical presentation. All the described patients show
the most frequent RSTS signs such as columella below alae
nasi (5/5), broad thumbs/hallux (4/6, 5/6), and ptosis (4/6)
(Fig. 1), but also typical WDSTS clinical features such as
broad nasal tip (4/6), narrow palpebral fissures (5/6), and
hirsutism (3/6).
Discussion
Chromatinopathies define a group of diseases caused by
alterations in genes coding for components of the epigenetic
apparatus termed “writers, erasers, readers, and remo-
delers”. These proteins act in concert to control the chro-
matin opening and closing thus, regulating gene expression
by modification (i.e., methylation, acetylation, etc.) of his-
tones and DNA methylation [25].
Due to the clinical overlap between different chromati-
nopathies and the functional network between the epige-
netic components, pathogenic variants in a same “epigene”
could be responsible for overlapping and/or slightly dif-
ferent clinical presentation cases.
Accordingly, in a recent work we found that some RSTS-
like patients found negative for mutations in the two cau-
sative genes turned out to be carriers of variants in other
chromatinopathies genes such as KMT2D (associated to
Kabuki syndrome, KS; OMIM #147920), ASXL1 (asso-
ciated to Bohring–Opitz syndrome, BOS; OMIM #605039),
and KMT2A (associated to Wiedemann–Steiner syndrome
WDSTS; OMIM #605130) by WES analysis [24]. These
results strongly suggest a possible implication of defective
histone-modifying enzymes, other than CBP and p300, in
the pathogenesis of RSTS-like phenotype. These findings
are in line with the known significant phenotypic overlap
observed among Mendelian disorders involving the epige-
netic machinery which likely reflects the interconnected
pathways involved in the complex regulation of balance
between open and closed chromatin [25, 31].
In the present study, we used a custom NGS panel or
WES to screen RSTS patients who resulted negative for
mutations in CREBBP and EP300 and exome analysis in
one trio. We identified six different novel variants in
KMT2A (5/6 classified as pathogenic/likely pathogenic).
Pathogenic variants in this gene, coding for a member of the
Lysine methyltransferase 2 family cause the WDSTS.
The identified variants are de novo (for the 4/6 patients
whose parents are available) and unreported, but indis-
cernible for type and localization from variants described in
WDSTS patients. Interestingly, patients #208 and #221
display a more severe phenotype, although they are carriers
of variants predicted pathogenic and likely pathogenic
respectively. This is probably due to the involvement of
protein domain affected by the KMT2A variant, which in
patient #208 affects the AT hook domain, while in patient
#221 any specific domain is involved. However, lack of a
complete molecular picture for patient #221 (as adopted
child) unfortunately prevents depth genotype–phenotype
correlation. The clinical reevaluation shows that patients
display the typical RSTS features, more evident in child-
hood, but also some WDSTS specific signs with a peculiar
global clinical presentation, making difficult the correct
diagnosis. WDSTS is a recently defined rare chromatino-
pathy (first description in 1989) and its clinical signs show
several overlapping features with other chromatinopathies.
Nevertheless, peculiar clinical signs such as hypertrichosis
cubiti and a typical facial appearance are present in almost
all the WDSTS reported patients [4]. KMT2A variants are
reported also in one Coffin–Siris (CSS) patient (pt #K2431
in Bramswig et al. [20]), in two Cornelia de Lange syn-
drome (CdLS) patients (Yuan et al. [21], patient CdLS #3
and Parenti et al. [22], patient #1), in two patients with a
diagnosis of Kabuki syndrome (KS) (patients KS8 and
KS29 in Sobreira et al. [23]) and in another RSTS-like
patient from our previous cohort (Negri et al. [24], pt #103).
Recently, several papers [12–15, 17–19] report KMT2A
pathogenic variants in patients without the “obligate” spe-
cific WDSTS clinical feature showing a broader phenotypic
spectrum due to KMT2A alterations. All the above cited
clinical conditions and in particular WDSTS and RSTS
show several phenotypic overlapping (e.g., growth defi-
ciency, neurological/cognitive impairment, similar dys-
morphisms, and limb anomalies), as observed in our cohort,
but we can envisage also a shared molecular cause. In all
these cases, in fact, the causative variants affect a gene
coding an epigenetic player that, by modulating the inter-
connected DNA methylation and histone acetylation/
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methylation, define a correct and site-specific chromatin
opening/closing balance. A loss of a specific player could
perturb the equilibrium leading to similar consequences or
to a spectrum of overlapping clinical conditions.
Reports in literature point out that variants in the same
gene can lead to different phenotypes with a set of common
features indicative of a group of disorders. On the other
side, variants in different genes encoding proteins impli-
cated in the same cellular pathway can lead to the same
phenotype. The different clinical outcomes due to variants
in the same gene can be attributed not only to specific
genotype–phenotype correlations, but also, to stochastic
events occurring during development and the different
genetic background among patients [20, 32, 33].
In summary, using a NGS-dedicated approach, we found
KMT2A variants in six patients with an initial RSTS clinical
diagnosis, supporting that different mechanisms leading to
imbalance of chromatin opening/closing can converge to a
similar phenotype characterized by several overlapping
RSTS/WDSTS clinical signs. Moreover, these patients
show a moderately different spectrum of clinical findings,
suggesting that different KMT2A variants or allelic hetero-
geneity could contribute to the wide variability of observed
phenotypes of chromatinopathies.
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